Bank of New York Mellon Corp lowered its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 1.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 169,346 shares of the company's stock after selling 2,307 shares during the period. Bank of New York Mellon Corp owned approximately 0.59% of Krystal Biotech worth $26,530,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Hussman Strategic Advisors Inc. purchased a new position in Krystal Biotech during the fourth quarter worth $658,000. TimesSquare Capital Management LLC raised its position in Krystal Biotech by 39.1% in the 4th quarter. TimesSquare Capital Management LLC now owns 158,868 shares of the company's stock worth $24,888,000 after purchasing an additional 44,646 shares during the period. AlphaCentric Advisors LLC bought a new stake in Krystal Biotech in the fourth quarter worth about $231,000. Principal Financial Group Inc. boosted its position in shares of Krystal Biotech by 3.1% during the fourth quarter. Principal Financial Group Inc. now owns 123,453 shares of the company's stock valued at $19,340,000 after buying an additional 3,727 shares during the period. Finally, State of New Jersey Common Pension Fund D boosted its position in shares of Krystal Biotech by 19.3% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 11,803 shares of the company's stock valued at $1,849,000 after buying an additional 1,910 shares during the period. Hedge funds and other institutional investors own 86.29% of the company's stock.
In other news, CAO Kathryn Romano sold 750 shares of the firm's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the sale, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the transaction, the insider now owns 1,475,882 shares of the company's stock, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is owned by insiders.
Krystal Biotech stock traded up $3.82 during midday trading on Monday, hitting $183.75. 353,248 shares of the company's stock were exchanged, compared to its average volume of 292,557. The company has a market cap of $5.29 billion, a PE ratio of 61.45 and a beta of 0.87. The firm has a 50-day moving average of $161.18 and a two-hundred day moving average of $174.38. Krystal Biotech, Inc. has a 12 month low of $141.72 and a 12 month high of $219.34.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same period last year, the firm earned $0.30 earnings per share. The company's quarterly revenue was up 116.4% on a year-over-year basis. As a group, equities analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.
A number of brokerages recently issued reports on KRYS. Jefferies Financial Group began coverage on Krystal Biotech in a research note on Wednesday, March 5th. They set a "buy" rating and a $245.00 price target for the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $215.00 target price on shares of Krystal Biotech in a research report on Thursday, February 20th. Citigroup boosted their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research note on Thursday, February 20th. Chardan Capital raised their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a research note on Thursday, February 20th. Finally, HC Wainwright reissued a "buy" rating and issued a $221.00 price objective on shares of Krystal Biotech in a research report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Krystal Biotech currently has an average rating of "Buy" and a consensus price target of $220.00.
Get Our Latest Research Report on Krystal Biotech
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.